1. Home
  2. Stocks
  3. Mankind Share Price
  • Chart
  • Rating
  • Financials
  • Technicals
  • Volume
  • Result
  • Synopsis
  • Corp Action
  • MF Shareholding
  • Similar Stocks
  • FAQs

    • Mankind Pharma Share Price

    Large Cap
    ₹2,498.8
    + 67.4 (2.77%)
    • Advice
    • Hold
    14 September, 2024 18:53 BSE: 543904 NSE: MANKIND ISIN: INE634S01028

    Start SIP in Mankind Pharma

    Start SIP

    Mankind Pharma Performance

    Day Range

    • Low 2,448
    • High 2,565
    ₹ 2,498

    52 Week Range

    • Low 1,683
    • High 2,565
    ₹ 2,498
    • Open Price2,448
    • Previous Close2,431
    • Volume1050734

    Mankind Pharma Chart

    • Over 1 Month + 14.85%
    • Over 3 Month + 11.54%
    • Over 6 Month + 20.94%
    • Over 1 Year + 37.79%

    Mankind Pharma Key Statistics

    P/E Ratio 51
    PEG Ratio 1.6
    Market Cap Cr
    Price to Book Ratio 10.5
    EPS 42.8
    Dividend 0
    Relative Strength Index 66.36
    Money Flow Index 58.89
    MACD Signal 71.58
    Average True Range 80.46

    Mankind Pharma Investment Rating

    • Master Rating:

    • Mankind Pharma Ltd has an operating revenue of Rs. 10,649.58 Cr. on a trailing 12-month basis. An annual revenue growth of 20% is outstanding, Pre-tax margin of 23% is great, ROE of 20% is exceptional. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is comfortably placed above its key moving averages, around 9% and 12% from 50DMA and 200DMA. It has recently broken out of a base in its weekly chart and is trading around -2% from the pivot point (which is the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 78 which is a FAIR score but needs to improve its earnings, a RS Rating of 47 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at A- which is evident from recent demand for the stock, Group Rank of 133 indicates it belongs to a poor industry group of Medical-Products and a Master Score of C is fair but needs to improve. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has mediocre earnings and technical strength, there are superior stocks in the current market environment.

    EPS Strength

    Price Strength

    Buyer Demand

    Group Rank

    Mankind Pharma Financials
    IndicatorJun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023
    Oper Rev Qtr Cr 2,4032,1532,3592,4532,3001,872
    Operating Expenses Qtr Cr 1,8311,6051,7551,8181,7611,491
    Operating Profit Qtr Cr 572547603635539381
    Depreciation Qtr Cr 838290776967
    Interest Qtr Cr 644421
    Tax Qtr Cr 93918913911774
    Net Profit Qtr Cr 513454487473409281
    IndicatorMar 2024Mar 2023
    Total Revenue Annual Cr 9,5318,290
    Operating Expenses Annual Cr 6,9406,430
    Operating Profit Annual in Cr 2,3251,697
    Depreciation Cr 318270
    Interest Annual Cr 1528
    Tax Annual Cr 436315
    Net Profit Annual Cr 1,8231,248
    IndicatorMar 2024Mar 2023
    Cash from Operating Activity Annual Cr 1,9831,799
    Cash from Investing Activity Annual Cr -1,919-1,041
    Cash from Financing Annual Activity Cr -9-710
    Net Cash Flow Annual Cr 5548
    IndicatorMar 2024Mar 2023
    Total ShareHolders Funds Annual Cr 9,6247,784
    Fixed Assets Annual Cr 3,5923,637
    Total Non Current Assets Annual Cr 5,9275,854
    Total Current Assets Annual Cr 5,4903,517
    Total Assets Annual Cr 11,4189,371
    IndicatorMar 2024Mar 2023
    Book Value Per Share Annual Rs 240194
    ROE Annual % 1916
    ROCE Annual % 2320
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin % 2823
    IndicatorJun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023
    Oper Rev Qtr Cr 2,8932,4412,6072,7082,5792,053
    Operating Expenses Qtr Cr 2,2121,8502,0002,0251,9241,636
    Operating Profit Qtr Cr 682591607683655417
    Depreciation Qtr Cr 108105110968785
    Interest Qtr Cr 1199965
    Tax Qtr Cr 1259510313013084
    Net Profit Qtr Cr 536471454501494285
    IndicatorMar 2024Mar 2023
    Total Revenue Annual Cr 10,6168,878
    Operating Expenses Annual Cr 7,8006,849
    Operating Profit Annual in Cr 2,5351,901
    Depreciation Cr 398326
    Interest Annual Cr 3444
    Tax Annual Cr 458362
    Net Profit Annual Cr 1,9131,282
    IndicatorMar 2024Mar 2023
    Cash from Operating Activity Annual Cr 2,1521,813
    Cash from Investing Activity Annual Cr -2,082-1,054
    Cash from Financing Annual Activity Cr 5-740
    Net Cash Flow Annual Cr 7619
    IndicatorMar 2024Mar 2023
    Total ShareHolders Funds Annual Cr 9,3637,435
    Fixed Assets Annual Cr 4,8074,781
    Total Non Current Assets Annual Cr 5,3955,388
    Total Current Assets Annual Cr 6,5684,328
    Total Assets Annual Cr 11,9639,715
    IndicatorMar 2024Mar 2023
    Book Value Per Share Annual Rs 239190
    ROE Annual % 2017
    ROCE Annual % 2522
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin % 2723
    Invest in Mankind Pharma

    Mankind Pharma Technicals

    EMA & SMA

    Current Price
    ₹2,498.8
    + 67.4 (2.77%)
    pointer
    • Bullish Moving Average
    • ___
    • 16
    • Bearish Moving Average
    • ___
    • 0
    • 20 Day
    • ₹2,384.65
    • 50 Day
    • ₹2,285.86
    • 100 Day
    • ₹2,225.60
    • 200 Day
    • ₹2,121.98
    • 20 Day
    • ₹2,403.96
    • 50 Day
    • ₹2,225.71
    • 100 Day
    • ₹2,208.17
    • 200 Day
    • ₹2,163.20

    Mankind Pharma Resistance and Support

    PIVOT
    ₹2,503.92
    Resistance
    First Resistance 2,559.83
    Second Resistance 2,620.87
    Third Resistance 2,676.78
    RSI 66.36
    MFI 58.89
    MACD Single Line 71.58
    MACD 68.54
    Support
    First Support 2,442.88
    Second Support 2,386.97
    Third Supoort 2,325.93

    Mankind Pharma Delivery and Volume

    Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
    Day 1,098,862 41,273,257 37.56
    Week 772,940 47,133,893 60.98
    1 Month 651,779 40,925,227 62.79
    6 Month 906,658 60,664,515 66.91

    Mankind Pharma Result Highlights

    Mankind Pharma Synopsis

    NSE-Medical-Products

    Mankind Pharma is involved in the business activities of Wholesale of pharmaceutical and medical goods. Company’s Total Operating Revenue is Rs. 9264.81 Cr. and Equity Capital is Rs. 40.06 Cr. for the Year ended 31/03/2024. Mankind Pharma Ltd. is a Public Limited Listed company incorporated on 03/07/1991 and has its registered office in the State of Delhi, India. Company’s Corporate Identification Number(CIN) is L74899DL1991PLC044843 and registration number is 044843.
    Market Cap 100,113
    Sales 9,368
    Shares in Float 10.02
    No of funds 495
    Yield
    Book Value 10.4
    U/D Vol ratio 1.3
    LTDebt / Equity
    Alpha 0.09
    Beta 0.47

    Mankind Pharma Shareholding Pattern

    Owner NameJun-24Mar-24Dec-23Sep-23
    Promoters 74.87%74.88%76.5%76.5%
    Mutual Funds 7.37%8.57%7.55%3.9%
    Insurance Companies 2.14%2.17%1.94%0.5%
    Foreign Portfolio Investors 11.58%9.87%6.74%4.18%
    Financial Institutions/ Banks
    Individual Investors 1.46%1.22%1.14%1.11%
    Others 2.58%3.29%6.13%13.81%

    Mankind Pharma Management

    Name Designation
    Mr. Ramesh Juneja Chairman & Wholetime Director
    Mr. Rajeev Juneja Vice Chairman & Mng.Director
    Ms. Sheetal Arora WholeTime Director & CEO
    Mr. Satish Kumar Sharma Whole Time Director
    Mr. Vivek Kalra Independent Director
    Mr. Tilokchand Punamchand Ostwal Independent Director
    Mr. Surendra Lunia Independent Director
    Mr. Bharat Anand Independent Director
    Ms. Vijaya Sampath Independent Director

    Mankind Pharma Forecast

    Price Estimates

    2,000(9.8%)
    1,758(-3.5%)
    1,590(-12.7%)

    Other Analyst Rating

    Mankind Pharma Corporate Action

    Date Purpose Remarks
    2024-07-31 Quarterly Results
    2024-05-15 Audited Results & Others To evaluate various options or proposals for raising funds through any of the permissible modes, subject to the receipt of necessary approvals.
    2024-01-31 Quarterly Results
    2023-10-31 Quarterly Results
    2023-08-02 Quarterly Results

    Mankind Pharma MF Shareholding

    Name Amount(cr)
    ICICI Prudential Bluechip Fund Growth 64,223
    ICICI Prudential Balanced Advantage Fund Growth 61,103
    SBI Bluechip Fund Regular Growth 51,633
    ICICI Prudential Equity & Debt Fund Growth 40,095
    SBI Contra Fund Regular Payout Inc Dist cum Cap Wdrl 39,433

    Mankind Pharma FAQs

    What is Share Price of Mankind Pharma ?

    Mankind Pharma share price is ₹2,498 As on 14 September, 2024 | 18:39

    What is the Market Cap of Mankind Pharma ?

    The Market Cap of Mankind Pharma is ₹100112.9 Cr As on 14 September, 2024 | 18:39

    What is the P/E ratio of Mankind Pharma ?

    The P/E ratio of Mankind Pharma is 51 As on 14 September, 2024 | 18:39

    What is the PB ratio of Mankind Pharma ?

    The PB ratio of Mankind Pharma is 10.5 As on 14 September, 2024 | 18:39

    Q2FY23
    Open Free Demat Account

    Be a part of 5paisa community - The first listed discount broker of India.

    +91
     
    footer_form

    CIN: L67190MH2007PLC289249 | Stock Broker SEBI Regn.: INZ000010231 | SEBI RA Regn.: INH000004680 | SEBI Depository Regn.: IN DP CDSL: IN-DP-192-2016 | AMFI-registered Mutual Fund Distributor | AMFI REGN No.: ARN-104096 | Date of initial Registration: 30/07/2015 | Current validity of ARN : 30/07/2027 | NSE Member id: 14300 | BSE Member id: 6363 | MCX Member ID: 55945 | Investment Adviser Regn No: INA000014252 | Registered Address - IIFL House, Sun Infotech Park, Road no. 16V, Plot no. B-23, MIDC, Thane Industrial Area, Waghle Estate, Thane, Maharashtra - 400604

    *Brokerage will be levied flat fee/executed order basis and not on a percentage basis. Flat fee of ₹10/order is available with Power Investor & Ultra Trader Packs. Investment in securities market are subject to market risk, read all related documents carefully before investing. Digital account would be opened after all procedure relating to IPV and client due diligence is completed. If sale/ purchase value of share of ₹10/- or less, a maximum brokerage of 25 paisa per share may be collected. Brokerage will not exceed the SEBI prescribed limit.

    Compliance Officer: Ms. Namita Godbole, Email: support@5paisa.com, Support Desk Helpline: 8976689766

    Contact Us

    Attention Investors

    • 1. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.
    • 2. Message from Exchange(s): Prevent Unauthorised transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day. Issued in the interest of investors.
    • 3. Message from Depositories: a) Prevent Unauthorized Transactions in your demat account --> Update your mobile number with your Depository Participant. Receive alerts on your registered mobile for all debit and other important transactions in your demat account directly from CDSL on the same day issued in the interest of investors. b) KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.

    Email: support@5paisa.com

    Support Desk Helpline: 8976689766

    ©2024, 5Paisa Capital Ltd. All Rights Reserved. We are ISO 27001:2013 Certified.